Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on GE HealthCare (GEHC) to $87 from $89 and keeps an Overweight rating on the shares. The firm notes the company delivered a beat on the top line and EPS of $1.07 was ahead of both consensus and Wells Fargo’s estimates. EBIT margins were down 150bps year-over-year, but above the firm’s estimates. GE HealthCa raised the lower end of 2025 EPS guidance, but Flyrcado to be less than $30M in 2025 sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE Healthcare Technologies Inc.: Strong Q3 Performance Overshadowed by Conservative Guidance and Cautious Product Launch
- GE HealthCare Reports Robust Q3 2025 Growth
- GE HealthCare price target lowered to $87 from $89 at BTIG
- Balanced Outlook on GE Healthcare Technologies Inc: Hold Recommendation Amid Market Uncertainties
- GE HealthCare price target raised to $80 from $74 at Morgan Stanley